Bristol Myers Squibb's planned launch of Sotyktu (deucravacitinib) for psoriatic arthritis has generated notable awareness among U.S. rheumatologists, with approximately one-third viewing the treatment as a meaningful therapeutic advance, according to research from Spherix Global Insights. The survey of 104 rheumatologists was conducted ahead of the FDA's scheduled March 6, 2026 decision on the oral Janus kinase inhibitor.
Despite the positive clinical reception, market analysts project a more modest commercial trajectory for the asset. BMS currently maintains the lowest market position among major pharmaceutical companies operating in the rheumatology specialty, and projections suggest Sotyktu will capture approximately one-fifth of psoriatic arthritis patients through competitive share shifts rather than expanding the overall market. This redistribution pattern indicates that adoption will likely come at the expense of existing therapies rather than through incremental patient acquisition.
The Sotyktu launch represents a strategic inflection point for BMS in the rheumatology segment. Successfully establishing the drug's market presence will be critical for the company to improve its competitive standing in a therapeutic area dominated by larger, more entrenched rivals. Market penetration rates and prescriber adoption patterns following the FDA decision will determine whether the launch achieves its potential to meaningfully strengthen BMS's position in specialty care.